196 related articles for article (PubMed ID: 32327479)
1. [
Glicksman RM; Metser U; Valliant J; Chung PW; Fleshner NE; Bristow RG; Green D; Finelli A; Hamilton R; Stanescu T; Hussey D; Catton C; Gospodarowicz M; Warde P; Bayley A; Breen S; Vines D; Jaffray DA; Berlin A
BMJ Open; 2020 Apr; 10(4):e035959. PubMed ID: 32327479
[TBL] [Abstract][Full Text] [Related]
2. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
7. Patterns of disease detection using [
Koschel S; Taubman K; Sutherland T; Yap K; Chao M; Guerrieri M; Benson A; Starmans M; Byrne G; Ong G; Macleod C; Foo M; Wong LM; Gyomber D; Ng M
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3712-3722. PubMed ID: 33852051
[TBL] [Abstract][Full Text] [Related]
8. Effect of
Metser U; Zukotynski K; Mak V; Langer D; MacCrostie P; Finelli A; Kapoor A; Chin J; Lavallée L; Klotz LH; Hagerty M; Hildebrand C; Bauman G
Radiology; 2022 May; 303(2):414-422. PubMed ID: 35076300
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of
Morris MJ; Rowe SP; Gorin MA; Saperstein L; Pouliot F; Josephson D; Wong JYC; Pantel AR; Cho SY; Gage KL; Piert M; Iagaru A; Pollard JH; Wong V; Jensen J; Lin T; Stambler N; Carroll PR; Siegel BA;
Clin Cancer Res; 2021 Jul; 27(13):3674-3682. PubMed ID: 33622706
[TBL] [Abstract][Full Text] [Related]
10. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
12. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
14. [
Oprea-Lager DE; Gontier E; García-Cañamaque L; Gauthé M; Olivier P; Mitjavila M; Tamayo P; Robin P; García Vicente AM; Bouyeure AC; Bailliez A; Rodríguez-Fernández A; Mahmoud SB; Vallejo-Casas JA; Maksud P; Merlin C; Blanc-Durand P; Drouet C; Tissot H; Vierasu I; Vander Borght T; Boos E; Chossat F; Hodolic M; Rousseau C
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3439-3451. PubMed ID: 37341747
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
17.
Metser U; Ortega C; Hussey D; Chan R; Berlin A; Finelli A; Veit-Haibach P
Curr Oncol; 2021 Aug; 28(5):3251-3258. PubMed ID: 34449586
[TBL] [Abstract][Full Text] [Related]
18. LUNAR: a randomized Phase 2 study of
Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
[TBL] [Abstract][Full Text] [Related]
19.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
20. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
Mena E; Shih J; Chung JY; Jones J; Rabiee A; Monge C; Turkbey B; Lindenberg L; Salerno KE; Kassin M; Wood B; Hernandez J; Maass-Moreno R; Saboury B; Jakhete N; Molitoris JK; Unger KR; Choyke PL; Escorcia FE
PLoS One; 2022; 17(11):e0277407. PubMed ID: 36367894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
